Comparative Pharmacology
Head-to-head clinical analysis: CYCLAPEN W versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAPEN W versus VEETIDS.
CYCLAPEN-W vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has a similar spectrum to ampicillin but with increased acid stability and oral absorption.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
0.5-1 hour in adults with normal renal function; prolonged to 2-6 hours in renal impairment.
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Primarily renal (90-100% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic